Skip to main content
Premium Trial:

Request an Annual Quote

Decode, Illumina to Co-develop, Sell Molecular Diagnostics

NEW YORK, May 15 (GenomeWeb News) - Decode Genetics and Illumina plan to co-develop and commercialize DNA-based diagnostics in several major disease areas, the firms said today.

 

According to the firms, the partnership will use Illumina's platform for high-multiplex SNP-genotyping to develop diagnostics for gene variants that Decode has shown to be risk factors for various diseases.

 

Under the terms of the agreement, Illumina will gain access to disease-related biomarkers, which will be jointly validated as diagnostic panels. Illumina will market and sell these on its forthcoming BeadXpress platform, the partners said.

 

Illumina will also install its SNP-genotyping platform at Decode's labs in Iceland.

 

Initially, the companies will focus on the gene encoding leukotriene A4 hydrolase, which has been linked to heart attack; the gene encoding transcription factor 7-like 2, which is linked to type II diabetes; and the gene encoding BARD1, which is linked to breast cancer.

 

The companies will share development costs and split the profits from sales of the diagnostics tests.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.